

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/736,732	12/16/2003	Baoshun Liu	27053/2082	3560
29933	7590 03/02/2005		EXAM	INER
PALMER & DODGE, LLP KATHLEEN M. WILLIAMS			MCKENZIE,	THOMAS C
111 HUNTINGTON AVENUE			ART UNIT	PAPER NUMBER
BOSTON, MA 02199			1624	

DATE MAILED: 03/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
055 - 4-45 - 0	10/736,732	LIU, BAOSHUN		
Office Action Summa	Examiner	Art Unit		
	Thomas McKenzie, Ph.D.	1624		
	nmunication appears on the cover sheet with	the correspondence address		
eriod for Reply	00 500 050 1/10 055 50 5/10 5	ITIVO) EDOM		
THE MAILING DATE OF THIS COM	OD FOR REPLY IS SET TO EXPIRE <u>2</u> MON MUNICATION	NTH(S) FROM		
- Extensions of time may be available under the pro	visions of 37 CFR 1.136(a). In no event, however, may a reply	be timely filed		
after SIX (6) MONTHS from the mailing date of th - If the period for reply specified above is less than	thirty (30) days, a reply within the statutory minimum of thirty (3	0) days will be considered timely.		
	num statutory period will apply and will expire SIX (6) MONTHS or reply will, by statute, cause the application to become ABANI			
Any reply received by the Office later than three n earned patent term adjustment. See 37 CFR 1.70	onths after the mailing date of this communication, even if time 4(b).	ely filed, may reduce any		
Status				
_	a) filed on 16 December 2002			
2a) This action is FINAL .	Responsive to communication(s) filed on <u>16 December 2003</u> . This action is FINAL . 2b) This action is non-final.			
'=	<i>'</i> —	nracacution as to the marite is		
•	dition for allowance except for formal matters	-		
closed in accordance with the	oractice under Ex parte Quayle, 1935 C.D. 1	1, 455 O.G. 215.		
Disposition of Claims				
4) Claim(s) 1-8 is/are pending in	he application.	•		
4a) Of the above claim(s)	_ is/are withdrawn from consideration.			
5) Claim(s) <u>1-8</u> is/are allowed.				
6) Claim(s) is/are rejected.				
7) Claim(s) is/are objected	to.			
8) Claim(s) are subject to	estriction and/or election requirement.			
Application Papers				
9)⊠ The specification is objected to	by the Examiner			
·	s/are: a) □ accepted or b) □ objected to by	the Examiner.		
	objection to the drawing(s) be held in abeyance			
· · · · · · · · · · · · · · · · · · ·	luding the correction is required if the drawing(s)	` ·		
	ted to by the Examiner. Note the attached C	- , ,		
Priority under 35 U.S.C. § 119				
12)⊠ Acknowledgment is made of a	claim for foreign priority under 35 U.S.C. § 1	19(a)-(d) or (f).		
a)⊠ All b)□ Some * c)□ None		.,.,		
	iority documents have been received.			
<u> </u>	iority documents have been received in App	lication No		
	pies of the priority documents have been re			

Attachment(s)

1) Notice of

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 2/19/04.

4) 🔲	Interview Summary (PTO-413)
	Paper No/c/Mail Date

5) Notice of Informal Patent Application (PTO-152)

6) Other: ____.

application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Application/Control Number: 10/736,732 Page 2

Art Unit: 1624

DETAILED ACTION

1. This action is in response to an application filed on 12/16/03. There are eight claims pending and eight under consideration. Claims 1, 2, and 4 are compound claims. Claims 5 and 6 are composition claims. Claims 7 and 8 are method of using claims. Claims 3 are method of making claims. This is the first action on the merits. The application concerns some 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one compounds, compositions, and uses thereof.

Abstract

2. Applicant is reminded of the proper content of an abstract of the disclosure. A patent abstract is a concise statement of the technical disclosure of the patent and should include that which is new in the art to which the invention pertains. In chemical patent abstracts for compounds or compositions, the general nature of the compound or composition should be given as well as its use, *e.g.*, "The compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics." The abstract is too short and generic. Examiner suggests claim 1, including the figure, and the utility.

Title

3. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The following title is suggested: addition of the word "1,6-Dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one" after the word "New".

Application/Control Number: 10/736,732 Page 3

Art Unit: 1624

Allowable Subject Matter

4. Claims 1-8 are allowed. The following is an examiner's statement of reasons for allowance: both Bell ('534) and Piazza ('980) teach the compound with registry number 139755-82-1 and shown below. The compound pictured in formula

I' differs from the compound pictured above by the addition of two methyl groups to positions 2 and 6 of the piperazine. While both Bell ('534) and Piazza ('980) suggest the addition of one alkyl group to this piperazine ring, neither has a teaching to add two alkyl groups. Thus, the claimed compounds are not made obvious by either one of these two references.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".

Conclusion

5. This application is in condition for allowance except for the following formal matters: the title and abstract as discussed above. Prosecution on the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453

Application/Control Number: 10/736,732

Art Unit: 1624

O.G. 213. A shortened statutory period for reply to this action is set to expire

TWO MONTHS from the mailing date of this letter.

6. Information regarding the status of an application should be obtained from

the Patent Application Information Retrieval (PAIR) system. Status information

for published applications may be obtained from either Private PAIR or Public

PAIR. Status information for unpublished applications is available through Private

PAIR only. For more information about the PAIR system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system,

contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free). Please

direct general inquiries to the receptionist whose telephone number is (703) 308-

1235.

7. Please direct any inquiry concerning this communication or earlier

communications from the Examiner to Thomas C McKenzie, Ph. D. whose

telephone number is (571) 272-0670. The FAX number for amendments is (571)

273-8300. The PTO presently encourages all applicants to communicate by FAX.

The Examiner is available from 9:00am to 5:30pm, Monday through Friday. If

attempts to reach the Examiner by telephone are unsuccessful, please contact

James O. Wilson, acting SPE of Art Unit 1624, at (571)-272-0661.

Thomas C. McKenzie, Ph.

Page 4

Primary Examiner

Art Unit 1624

TCMcK/me